Oxford Centre for Diabetes, Endocrinology and Metabolism

OCDEM is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, we aim to enhance understanding of these diseases and to accelerate the search for new treatments and cures.

Head of OCDEM

Fredrik Karpe

Professor of Metabolic Medicine

fredrik.karpe@ocdem.ox.ac.uk

+44 (0)1865 857222

About OCDEM

The Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM) is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases.

Gene that contributes to female body shape may increase risk of type 2 diabetes

Scientists at the University of Oxford have identified a gene that in women is linked to the creation and location of new fat cells and in turn contributes to an increased risk of type 2 diabetes.

Diabetes Trials Unit

The Diabetes Trials Unit (DTU) is a fully registered UKCRC Clinical Trials Unit, specialising in performing national and multinational clinical trials related to diabetes.

Title TBC

Friday, 24 January 2020, 12.45pm to 2pm
Targeting bromodomain and extra-terminal domain proteins as a novel therapeutic approach for pancreatic neuroendocrine tumours

Friday, 31 January 2020, 12.45pm to 2pm
Investigating the modulation of KRAS signalling in PNET and PDACs using epigenetic targeting compounds

Friday, 31 January 2020, 12.45pm to 2pm
Title TBC

Friday, 07 February 2020, 12.45pm to 2pm
Title TBC

Friday, 14 February 2020, 12.45pm to 2pm

Latest Publications

δ-cells and β-cells are electrically coupled and regulate α-cell activity via somatostatin.

Briant LJB. et al, (2018), J Physiol, 596, 197 - 215

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Mentz RJ. et al, (2017), Am Heart J, 187, 1 - 9

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR. et al, (2017), Lancet Diabetes Endocrinol, 5, 877 - 886

Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation.

Howles SA. et al, (2017), JCI Insight, 2

Latest News

Ocdem researcher wins british endocrinology society prize

Events

View previous and upcoming events in OCDEM.

Find out more

Oxford Centre for Diabetes, Endocrinology and Metabolism

OCDEM is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, we aim to enhance understanding of these diseases and to accelerate the search for new treatments and cures.

In this section

Head of OCDEM

Fredrik Karpe

About OCDEM

Gene that contributes to female body shape may increase risk of type 2 diabetes

Diabetes Trials Unit

Seminars and Events

Title TBC

Targeting bromodomain and extra-terminal domain proteins as a novel therapeutic approach for pancreatic neuroendocrine tumours

Investigating the modulation of KRAS signalling in PNET and PDACs using epigenetic targeting compounds

Title TBC

Title TBC

Latest Publications

δ-cells and β-cells are electrically coupled and regulate α-cell activity via somatostatin.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Cinacalcet corrects hypercalcemia in mice with an inactivating Gα11 mutation.

Latest News

OCDEM researcher wins British Endocrinology Society prize

OCDEM staff sweep up awards

Study decodes gene function that protects against type 2 diabetes

Professor David Ray awarded 2020 Society for Endocrinology medal

OCDEM Vacancies

Events